On-Demand Programs
Contemporary Considerations in the Efficacy, Safety, and Implementation of Bispecific Antibody Therapy in NHL
This educational program is an interactive, multi-faculty, debate-style program that will discuss the need for bispecific antibodies in the management of non-Hodgkin’s lymphoma (NHL), summarize the current clinical data informing the use of bispecific antibodies, potential adverse events associated with the bispecific antibody therapy in NHL, and the role of multidisciplinary team in the optimal diagnosis, treatment and management of NHL. This program also consists of a video case study, and interviews of a nurse and a patient advocate that will discuss the importance of interdisciplinary care and patient advocacy in the treatment of patients with NHL.
RELEASED DATE: October 10, 2024
EXPIRATION DATE: October 10, 2025
Key Updates in Bispecific Antibodies in NHL Management—Unmet Needs and Opportunities for Improved Management in Later-Line Management
This enduring TeleECHO educational series is designed to assist members of the multi-disciplinary oncology care team in identifying approaches to the use of novel bispecific antibody therapies in later-line management of B-cell non-Hodgkin's lymphoma (NHL). This program features expert analysis of the latest clinical trial outcomes and potential adverse events associated with bispecific antibody therapy, as well as discussion of best practices for multidisciplinary management of B-cell NHL to improve long-term clinical outcomes.
RELEASED DATE: January 26, 2024
EXPIRATION DATE: January 26, 2025
Updates for VA Clinicians in the Use of Bispecific Antibodies Across Later-Line Non-Hodgkin’s Lymphomas: Summarizing Current Efficacy and Safety Data
This enduring is designed to assist veterans’ affairs-associated members of the multi-disciplinary oncology care team in evaluating current developments in the use of novel bispecific antibody therapies in later-line management of Non-Hodgkin’s Lymphoma (NHL). This program features expert analysis of the latest clinical trial outcomes and current efficacy and safety data associated with adverse event management in NHL.
RELEASED DATE: January 18, 2024
EXPIRATION DATE: January 18, 2025
Updates for VA Clinicians in the Use of Bispecific Antibodies Across Later-Line Non-Hodgkin’s Lymphomas: Summarizing Current Efficacy and Safety Data (Podcasts)
Non-Hodgkin’s Lymphoma accounts for about 4% of cancers in the US. It also affects the VA population and is majorly caused due to exposure to toxic substances. In this podcast, we will discuss the current treatments, adverse events and management of VA NHL patients. We will cover diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL).
RELEASED DATE: January 25, 2024
EXPIRATION DATE: January 25, 2025
